137 related articles for article (PubMed ID: 16081472)
1. Interferon-alpha as maintenance therapy in patients with multiple myeloma.
Yalcin B; Dogan M; Buyukcelik A; Doruk H; Tek I; Demirkazik A
Ann Oncol; 2005 Dec; 16(12):1981. PubMed ID: 16081472
[No Abstract] [Full Text] [Related]
2. Interferon and multiple myeloma.
Lauta VM
Med Oncol; 1995 Mar; 12(1):63-9. PubMed ID: 8542250
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
[TBL] [Abstract][Full Text] [Related]
4. [Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma].
García Laraña J; Díaz Mediavilla J; Martínez R; Lahuerta JJ; Alegre A; Odriozola J; Sureda A; San Miguel J; De la Rubia J; Escudero A; Conde E; Bladé J; Cabrera R; Gastearena J; Besalduch J; Vidal MJ; Hernández F; Rifon J; Leon A; Mataix R; Parody R; Moraleda JM; Solano C; de Pablos JM; Sánchez JJ
Sangre (Barc); 1997 Apr; 42 Suppl 1():38-41. PubMed ID: 9381300
[No Abstract] [Full Text] [Related]
5. Interferon in multiple myeloma--summary of treatment results and clinical implications.
Ludwig H; Fritz E
Acta Oncol; 2000; 39(7):815-21. PubMed ID: 11145439
[TBL] [Abstract][Full Text] [Related]
6. Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial.
Offidani M; Olivieri A; Montillo M; Rupoli S; Centurioni R; Alesiani F; Marchegiani G; Pieroni S; Catarini M; Pelliccia G; Altilia F; Leoni P
Haematologica; 1998 Jan; 83(1):40-7. PubMed ID: 9542322
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha in the treatment of multiple myeloma.
Khoo TL; Vangsted AJ; Joshua D; Gibson J
Curr Drug Targets; 2011 Mar; 12(3):437-46. PubMed ID: 21143148
[TBL] [Abstract][Full Text] [Related]
8. Interferon does not prevent leukemic evolution in patients with multiple myeloma.
Remes K; Paul R; Pelliniemi TT
Leukemia; 1993 Jul; 7(7):1072-3. PubMed ID: 8321024
[No Abstract] [Full Text] [Related]
9. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
[TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
11. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults.
Drayson MT; Chapman CE; Dunn JA; Olujohungbe AB; Maclennan IC
Br J Haematol; 1998 Apr; 101(1):195-202. PubMed ID: 9576201
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin.
Hiyoshi M; Hashimoto S; Ota T; Nakao T; Takubo T; Tagawa S; Tatsumi N
Haematologia (Budap); 1997; 28(3):177-80. PubMed ID: 9283919
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for interferon alfa in multiple myeloma.
Ludwig H; Fritz E; Neuda J; Durie BG
J Clin Oncol; 1997 Apr; 15(4):1672-9. PubMed ID: 9193368
[TBL] [Abstract][Full Text] [Related]
15. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
Björkholm M
Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
[No Abstract] [Full Text] [Related]
16. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
17. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment of multiple myeloma with alpha interferon versus an alternating schedule of alpha interferon and chemotherapy. Greek Myeloma Study Group (GMSG).
Maniatis A
Eur J Cancer; 1991; 27 Suppl 4():S49-50. PubMed ID: 1799479
[No Abstract] [Full Text] [Related]
19. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy and supportive care for patients with multiple myeloma.
Kyle RA
Semin Oncol; 1999 Oct; 26(5 Suppl 13):35-42. PubMed ID: 10528893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
